Business Research Company sees Zynteglo market growth through 2035
The Business Research Company says the Zynteglo market is positioned for growth as gene therapy, personalized medicine and rare-disease investment accelerate. The report also says North America led the market in 2025 and highlights beta-thalassemia prevalence and healthcare infrastructure as key demand drivers.
Why it matters: - Zynteglo is a gene therapy aimed at treating beta-thalassemia at its source, which could reduce or eliminate the need for regular blood transfusions. - The market outlook matters because the therapy sits at the intersection of rare-disease care, gene editing and curative hematology. - The report frames Zynteglo as part of a broader shift toward one-time treatments for inherited blood disorders.
What happened: - The Business Research Company released its Zynteglo Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report says the Zynteglo market is drawing increasing attention as genetic therapy advances evolve. - The company says the historical market expansion was supported by rising transfusion-dependent beta-thalassemia, long-term transfusion burdens, growth in genetic disease treatment centers, stem cell modification progress and early gene-therapy approvals. - The forecast period is expected to be driven by commercialization of gene editing therapies, higher investment in rare genetic disease treatments, expanded personalized medicine infrastructure, a stronger focus on curative hematology and more healthcare funding for genetic disorders. - North America held the largest share of the global Zynteglo market in 2025.
The details: - Zynteglo modifies a patient’s stem cells so they can produce functional hemoglobin. - The therapy is designed to address the underlying cause of beta-thalassemia rather than manage symptoms only. - The report says the approach is intended to reduce or eliminate dependence on regular transfusions for people with transfusion-dependent beta-thalassemia. - The company identifies rising thalassemia prevalence worldwide as a major market driver. - Factors behind that rise include high carrier rates in some populations, consanguineous marriages, migration patterns, limited awareness and screening, improved diagnostics and better patient survival. - The American Society of Hematology reported that beta-thalassemia prevalence in the US was about 3,665 cases in 2023, or 1.07 per 100,000 people. - The report says healthcare infrastructure growth supports Zynteglo adoption by improving diagnosis and patient management. - Healthcare construction activities in the UK reached £4.8 billion in 2024, up 18% from 2023, according to Sports Medical. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis and updated graphics and tables. - The company posted a free sample of the report and the full market report.
Between the lines: - The report points to a market moving from experimental promise toward broader commercial use. - Demand appears tied not just to disease prevalence, but also to whether health systems can support advanced cell and gene therapies. - North America’s lead suggests the region’s reimbursement, research and clinical infrastructure may be ahead of other markets in absorbing this therapy class.
What's next: - The company expects growth to continue through 2035 as gene editing therapies become more commercialized. - Wider adoption will likely depend on funding, infrastructure and the pace of regulatory and clinical uptake in key regions. - The report signals more competition around curative treatments for blood disorders as personalized medicine expands.
The bottom line: - Zynteglo’s market thesis rests on a simple bet: if gene therapy can scale, transfusion-heavy care for beta-thalassemia could shift toward one-time curative treatment.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
American Business Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.